Is the business good?
How good a business is INDV?
Indivior Pharmaceuticals, Inc. keeps 32% of every revenue dollar as operating profit, against 12% for the median Drug Manufacturers - Specialty & Generic name.
32%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q2 2026
- Cash conversion
- −0.31×
Cash conversion · 1.60× a year ago · some of the reported profit has not turned into cash yet
- Share count, year on year
- −1.6%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 6.2%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2022 | −9.0% |
| FY2023 | −14% |
| FY2024 | 3.2% |
| FY2025 | 21% |
Details›
- Gross margin12 months to Q2 2026
- 82%
- Operating margin12 months to Q2 2026
- 32%
- Net margin12 months to Q2 2026
- 27%
- Free cash flow margin
- −8.3%
- R&D as % of revenue
- 6.2%
- Revenue, trailing twelve months
- $1.33B
- Free cash flow, trailing twelve months
- −$111M
- Net income, trailing twelve months
- $355M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #23 of 28 by Smart Score